TY - T1的多民族人口主要扭力肌张力障碍的发生率(S53.001) JF -神经学乔-神经病学SP S53.001 LP - S53.001六世- 80 - 7补充非盟-卡洛琳·坦纳盟凯萨首页琳Albers AU -塞缪尔高盛盟Jeffrey Klingman AU - Raymond Lo盟康尼马拉AU -紫水晶Leimpeter AU -罗宾Fross盟Zhuqin顾AU -罗宾Smit盟Annelie de Kleijn AU -格蕾丝Bhudhikanok盟劳里Ozelius AU -苏珊Bressman盟瑞秋Saunders-Pullman AU -辛西娅·考米拉盟Lorene Nelson AU -斯蒂芬·范Eeden Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/S53.001.abstract N2 -目的:确定主要扭力肌张力障碍的发病率(输配电)在一个大民族,健康维护组织集成。背景:输配电发病率据估计在只有少数研究中,代表少于120例。DESIGN/METHODS: PTD cases were identified in the > 3 million members of Kaiser Permanente Northern California (KPNC) for the period 2003-2007. Individuals with any diagnostic code for dystonia were identified. A complete chronological list of all health care utilizations was reviewed for each individual. Final diagnostic classification was determined by consensus of two movement disorders specialists, including when possible a neurological examination with standardized videotape data collection. Average annual incidence was calculated for each dystonia subtype and for PTD overall, and for gender-, race/ethnicity- and age-specific groups. Direct standardization of rates for age and gender used the 2000 U.S. census population.RESULTS: From 7,769 records identified for review, 741 qualified as incident PTD, with 78% being white. Incidence per 105 person-years was: all PTD 4.4 (95% CI 4.08,4.72), blepharospasm 1.7 (1.5,1.89), cervical dystonia 1.31 (1.13,1.5), laryngeal dystonia 0.81 (0.67, 0.94), limb 0.74 (0.6, 0.85), oromandibular 0.37 (0.28, 0.46), generalized 0.04 (0.01, 0.07). Blepharospasm, cervical dystonia and laryngeal dystonia were more common in women than in men.CONCLUSIONS: PTD incidence is estimated based on more than eleven times as many cases as the next largest study. Incidence estimates were higher for most dystonia subtypes, compared to prior estimates. Since PTD may be missed even in this equal access health care system, our estimates are likely to be conservative.Supported by: NIH 1RO1 NS046340; AHRQ RO1 HS018413; Dystonia Medical Research Foundation; Kaiser Permanente Northern California, James & Sharron Clark.Disclosure: Dr. Tanner has received personal compensation for activities with Adamas Pharmaceuticals as a consultant. Dr. Albers has nothing to disclose. Dr. Goldman has nothing to disclose. Dr. Klingman has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Marras has received personal compensation for activities with Solvay Pharmaeuticals as a consultant. Dr. Leimpeter has nothing to disclose. Dr. Fross has nothing to disclose. Dr. Gu has nothing to disclose. Dr. Smit has nothing to disclose. Dr. de Kleijn has nothing to disclose. Dr. Bhudhikanok has nothing to disclose. Dr. Ozelius has nothing to disclose. Dr. Bressman has received a royalty, liscense fee or contractual rights payment from Beth Israel/Mount Sinai/Athena. Dr. Saunders-Pullman has nothing to disclose. Dr. Comella has received personal compensation for activities with Ipsen, Merz, Allergan and NeuPathe and Medtronic as a consultant. Dr. Comella has received research support from Ipsen, Merz, Allergan, NIH, Dystonia Study Group. Dr. Nelson has received personal compensation for activities with Goldberg and Segalla. Dr. Van Den Eeden has received research support from GlaxoSmithKline, Inc.Thursday, March 21 2013, 2:00 pm-3:30 pm ER -